CJC-1295: the GHRH (1-29) analog and what the research covers

CJC-1295 (without DAC) is a synthetic analog of growth-hormone-releasing hormone, GHRH (1-29), reworked with a few targeted amino-acid substitutions that give it more stability than the native peptide. Because it doesn't carry the drug-affinity complex (DAC) that conjugated versions use, its pharmacokinetics in experimental systems line up with those of an unconjugated GHRH analog. It is one of the more commonly requested compounds in growth-hormone-axis research, usually as a tool for characterizing how the GHRH receptor binds and signals.

For laboratory research only. CJC-1295 is supplied strictly for in-vitro research. It has not been evaluated by the FDA, this page covers no dosing, administration, or use in humans or animals, and makes no therapeutic claims.

What CJC-1295 is (and the No-DAC point)

The single most important thing to fix before reading anything else about CJC-1295 is that it comes in two forms, and they are not interchangeable in a study design.

• CJC-1295 without DAC, also called Mod GRF 1-29, is the unconjugated peptide. It clears quickly in experimental models, in the manner typical of a GHRH analog. This is the form we sell as the CJC-1295 single, and it is the form this guide is about.
• CJC-1295 with DAC carries a drug-affinity complex that binds serum albumin, which sharply lengthens how long the compound persists in a model. That variant is the one paired with Ipamorelin in the Hulk Stack; the Hulk Stack guide covers it.

Grabbing the wrong variant is not a small substitution: the exposure profiles are very different, so a protocol built around short, pulsatile exposure and one built around sustained receptor occupancy call for different material. When it matters, the certificate and the product name together tell you which one is in the vial.

The stabilizing substitutions are what separate CJC-1295 (No DAC / Mod GRF 1-29) from native GHRH (1-29). Native GHRH is degraded rapidly by peptidases; the substituted analog resists that breakdown better, which is why it is the more practical tool for bench work that needs the peptide to survive an assay.

What the research actually examines

It is worth separating what the primary literature measures from the broader claims that circulate around growth-hormone peptides, because the two are not the same thing.

In biochemical and cell-based models, CJC-1295 binds and activates the GHRH receptor on pituitary-derived cells, kicking off the intracellular signaling that underlies endocrine regulation. The published work looks at how it binds, how fast it activates the receptor, and the downstream signaling seen under short-exposure conditions. Researchers typically put it to work for:

• Mapping GHRH-receptor binding, activation, and signaling dynamics
• Studying growth-hormone-axis regulation and endocrine feedback loops
• Cell assays that track transcriptional and downstream signaling responses

As with any peptide of this kind, results move around with concentration, exposure time, and assay design, so it is a tool for characterizing GHRH-receptor signaling, not a stand-in for defined physiological outcomes. Most of this literature is in-vitro and preclinical, and a finding in one cell system does not automatically transfer to another, let alone to a whole organism. That gap between a receptor-level observation and a marketed benefit is exactly where careful reading pays off: a claim about what CJC-1295 "does" should be traced back to a study that used this compound, at a stated concentration, in a stated model.

Often paired with ipamorelin

One recurring thread in the literature is combining a GHRH analog with a growth-hormone secretagogue. That's why CJC-1295 and Ipamorelin are so often studied side by side: to see whether their receptor signaling converges or runs independently within the same model. The two engage different receptors on the same pituitary cells, so a single experimental system can feed two inputs into one readout. The CJC-1295 and Ipamorelin guide covers the pairing in depth, and the Hulk Stack guide covers the version of that pairing built on the DAC form.

Supply and format

CJC-1295 ships as a ready-to-use solution, each batch backed by its own Certificate of Analysis (HPLC for purity and mass spectrometry for identity) and kept refrigerated at 2-8°C. Supplying it pre-mixed removes the reconstitution step where most avoidable variability enters: solvent choice, added volume, mixing and the wait before first use all differ bench to bench, and a solution prepared under controlled conditions takes that variance off the table. Recent certificates can be viewed in the COA library before you order, and the peptide calculator handles the concentration math from the vial.

How it ships in the US

For US laboratories, CJC-1295 is supplied pre-mixed as a solution rather than a lyophilized powder, prepared under controlled conditions and HPLC-verified, with a batch-specific Certificate of Analysis (HPLC for purity, mass spectrometry for identity). Each batch is made in our own UK laboratory and independently checked in a US laboratory before any US order ships. Orders are dispatched cold-chain from the warehouse that serves the United States, with tracked delivery across the country next business day, priced in US dollars and payable by Visa, Mastercard or Apple Pay. Store refrigerated at 2-8°C on arrival, not frozen.

What CJC-1295 is not

• It is not an approved medicine in the United States or anywhere else, has not been evaluated by the FDA, and is not supplied for human or veterinary use.
• It is not the DAC form. The single we sell is the No-DAC peptide (Mod GRF 1-29); the DAC-conjugated variant behaves very differently and is sold only inside the Hulk Stack.
• It is not native GHRH. The amino-acid substitutions change its stability, so it should not be treated as interchangeable with unmodified GHRH (1-29) in a protocol.

Dosing and administration

We do not publish dosing, reconstitution-for-use or administration guidance for CJC-1295. The material is supplied strictly for in-vitro laboratory research and is not for use in humans or animals, so quantity guidance aimed at a person would be inconsistent with what is actually supplied. Experimental concentrations are specific to the model and endpoint and belong in the primary literature.

Related reading

• New to the subject? Start with what research peptides are.
• CJC-1295 and Ipamorelin
• What is the Hulk Stack?